Table 4.
Characteristics of patients with versus without NGS-identified or SBS-identified TDRM
| NGS |
SBS |
|||||
|---|---|---|---|---|---|---|
| Characteristic | TDRM, n = 25 | No TDRM, n = 55 | P-value | TDRM, n = 7 | No TDRM, n = 73 | P-value |
| Male, n (%) | 21 (84.0) | 43 (78.2) | 0.76 | 7 (100.0) | 57 (78.1) | 0.33 |
| Age, years, median (IQR) | 32 (19–46) | 30 (23–44) | 0.61 | 45 (24–52) | 30 (18–42) | 0.04 |
| Viral Load (log10 copies/ml), median (IQR) | 4.9 (4.3–5.8) | 5.8 (4.9–6.4) | 0.03 | 5.6 (5.4–5.9) | 5.5 (4.7–6.2) | 0.55 |
| CD4 (cells/mm3), median (IQR) (n = 50) | 427 (431–616), n = 15 | 408 (315–576), n = 35 | 0.83 | 429 (327–567) | 405 (317–585) | 0.98 |
| Risk group, n (%) | ||||||
| MSM | 15 (60.0) | 32 (58.2) | NS | 3 (42.9) | 44 (60.3) | 0.44 |
| OGE | 4 (16.0) | 12 (21.8) | 0.76 | 0 (0) | 16 (21.9) | 0.33 |
| Other* | 6 (24.0) | 11 (20.0) | 0.77 | 4 (57.1) | 13 (17.8) | 0.03 |
| HIV subtype, n (%) | ||||||
| B | 16 (64.0) | 32 (58.2) | 0.24 | 7 (100) | 41 (56.2) | <0.05 |
| C | 5 (20.0) | 12 (21.8) | 0.32 | 0 (0) | 17 (23.3) | 0.33 |
| Other | 4 (16.0) | 11 (20.0) | 0.27 | 0 (0) | 15 (20.0) | 0.33 |
| Diagnosis at later years, 2008–2014 | 15 (60.0) | 27 (49.1) | 0.47 | 6 (85.7) | 37 (50.7) | 0.16 |
| RT mutations, mean | 12.6 | 9.7 | 0.03 | 8.5 | 8.3 | 0.83 |
| PR mutations, mean | 9 | 8.4 | NS | 6.4 | 7.6 | 0.27 |
MSM – men who have sex with men; OGE – originating in countries with generalized epidemics; TDRM – transmitted drug resistance mutations; PR – protease; RT – reverse transcriptase; SBS – Sanger-based sequencing; NGS – next-generation sequencing. *Other subtypes- A, AG/G,and F.